ROCKVILLE, Md., Oct. 12 (HSMN NewsFeed) — Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda’s anti-psychotic, in the U.S….
Biopharmaceuticals, Licensing
Vanda Pharmaceuticals, Novartis Pharma AG, Fanapt, iloperidone

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia”
Leave a Comment